Understanding Pancreatic Cancer

Pancreatic cancer is among the most aggressive human malignancies, with poor prognosis when diagnosed at advanced stages. The pancreas is a 6-inch organ behind the stomach that produces digestive enzymes and hormones (insulin, glucagon) to regulate blood sugar. When cancerous cells develop in the pancreatic tissue, they grow rapidly and spread to adjacent organs and distant sites before causing detectable symptoms.

In India, pancreatic cancer incidence has been rising steadily, paralleling increasing rates of obesity, type 2 diabetes, and metabolic syndrome. Unlike Western countries where ductal adenocarcinoma dominates the disease field, India also sees significant burden of tropical chronic pancreatitis-associated pancreatic cancer, a unique epidemiological feature. Late presentation is a hallmark of Indian pancreatic cancer patients: 75-80% present with locally advanced or metastatic unresectable disease, substantially limiting surgical cure options.

The most critical factor in pancreatic cancer outcomes is stage at diagnosis. Patients diagnosed with resectable localized disease (20-25% of cases) have substantially better prognosis with aggressive multimodal therapy combining surgery, chemotherapy, and radiation. Modern systemic therapies including FOLFIRINOX, gemcitabine-based regimens, and targeted agents (olaparib for BRCA mutations, pembrolizumab for MSI-H tumors) have incrementally improved survival, though pancreatic cancer remains a major oncology challenge.

Types of Pancreatic Cancer

Signs and Symptoms

1. Painless jaundice: Yellowing of skin and eyes with pale stools and dark urine, often without abdominal pain, is the classic early warning sign. Caused by tumor obstruction of the common bile duct.
2. Upper abdominal pain: Pain in the epigastric region or right upper quadrant, sometimes radiating to the back. Pain typically worsens when lying flat and improves when leaning forward. May indicate local tumor invasion.
3. Loss of appetite and unexplained weight loss: Rapid weight loss (10-20 kg) despite maintained caloric intake, related to cancer cachexia and impaired nutrient absorption due to pancreatic insufficiency.
4. New-onset diabetes: Hyperglycemia appearing in adults without prior diabetes, caused by pancreatic tumor destroying insulin-producing beta cells. May precede cancer diagnosis by months.
5. Pale or gray stools: Fatty, floating stools (steatorrhea) due to impaired fat digestion when tumor obstructs pancreatic enzyme secretion into duodenum.
6. Digestive disturbances: Chronic diarrhea, fatty stools, and malabsorption symptoms related to pancreatic insufficiency and altered bile flow.
7. Fatigue and weakness: Profound tiredness, anemia, and poor physical endurance due to advanced disease, metabolic derangements, and tumor burden.
8. Abdominal distension and ascites: Swelling of the abdomen caused by fluid accumulation in peritoneal cavity, indicates advanced peritoneal involvement.
9. Itching (pruritus): Severe itching due to bile salt deposition in skin from obstructive jaundice.
10. Blood clots (DVT/PE): Thromboembolism is a paraneoplastic phenomenon in pancreatic cancer, requiring anticoagulation.

Most pancreatic cancers are silent in early stages; symptoms typically appear only after local invasion or metastasis. Painless jaundice with rapid onset warrants urgent diagnostic imaging. Symptoms lasting more than 2 weeks require evaluation by a specialist.

Risk Factors for Pancreatic Cancer

Multiple genetic, lifestyle, and medical factors elevate pancreatic cancer risk. In India, rising prevalence of obesity, diabetes, and chronic pancreatitis significantly increases population-level risk. Understanding personal risk profile enables targeted screening and early detection strategies.

Risk factor data from ICMR cancer registries, National Cancer Institute, AJCC, and Indian Journal of Cancer literature.

Diagnostic Evaluation for Pancreatic Cancer

Pancreatic cancer diagnosis requires a combination of clinical suspicion, imaging, biomarkers, and tissue confirmation. Imaging modality choice depends on clinical presentation, but CT or MRI with proper protocols is essential. Tissue diagnosis is obtained via endoscopic ultrasound-guided biopsy, percutaneous biopsy, or surgical sampling.

Pancreatic Cancer Staging System (AJCC 8th Edition (2017))

Pancreatic cancer staging follows the American Joint Committee on Cancer (AJCC) TNM classification, with tumor size (T), regional lymph node involvement (N), and distant metastases (M) determining overall stage. Resectability classification (resectable, borderline resectable, locally advanced unresectable, metastatic) is equally important for treatment planning. In India, 75-80% of patients present with unresectable disease due to late diagnosis.

Resectability assessment combines imaging, CA 19-9, and performance status. In India, late presentation (75-80% unresectable) limits cure opportunity. Borderline resectable tumors increasingly managed with perioperative chemotherapy to improve outcomes. Neoadjuvant FOLFIRINOX becomes standard for locally advanced resectable/borderline cases.

Treatment Modalities for Pancreatic Cancer

Surgical Resection

Surgery offers the only chance for cure in pancreatic cancer, but only 20-25% of patients present with resectable disease. The two primary resection procedures are pancreaticoduodenectomy (Whipple procedure) for head/neck tumors and distal pancreatectomy for body/tail tumors. Extended lymphadenectomy and en bloc resection of invaded adjacent organs (stomach, colon, portal vein) is often necessary.

Whipple procedure involves en bloc resection of pancreatic head, duodenum, proximal jejunum, distal stomach, common bile duct, and gallbladder, with reconstruction via pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy. Operative mortality in high-volume centers is 2-5%, with major morbidity (fistula, bleeding, infection) in 20-40% of cases. Distal pancreatectomy with splenectomy is used for body/tail tumors, with lower morbidity but higher risk of functional pancreatic insufficiency.

Margin-negative resection (R0) is essential for improved outcomes; R1 resection (microscopically positive margins) is associated with worse recurrence patterns and survival. In India, access to high-volume pancreatic surgery centers is limited outside major metropolitan areas. Patients should be referred to centers performing >20 pancreatic resections annually for optimal outcomes.

• Surgical techniques: Whipple procedure (pancreaticoduodenectomy)
• Distal pancreatectomy with splenectomy
• En bloc resection of invaded organs (stomach, portal vein, colon)
• Extended D2 lymphadenectomy
• Margin-negative (R0) resection goal

Adjuvant Chemotherapy (Post-Operative)

Adjuvant chemotherapy after surgical resection improves disease-free and overall survival in resected pancreatic cancer patients. The landmark ESPAC-4 trial demonstrated that adjuvant gemcitabine plus capecitabine improved median overall survival from 20.2 to 28.8 months compared to gemcitabine alone, with acceptable toxicity. More recently, the PRODIGE-24 trial showed that FOLFIRINOX-based adjuvant therapy (5-FU, oxaliplatin, irinotecan, leucovorin) improved median OS to 54.4 months versus 35 months with gemcitabine.

Adjuvant FOLFIRINOX is increasingly preferred for fit patients (ECOG PS 0-1, age <75) due to superior OS benefit, though with increased grade 3-4 toxicity compared to gemcitabine. Gemcitabine monotherapy is reserved for elderly patients or those with significant comorbidities precluding FOLFIRINOX. Treatment duration is typically 6 months of adjuvant systemic therapy after resection, either as standalone adjuvant or continuation of perioperative chemotherapy (neoadjuvant + adjuvant).

Timing is critical: adjuvant therapy should begin within 4-6 weeks of resection once patients recover from surgery, as delayed initiation (>8 weeks post-op) adversely affects outcome. In India, availability of FOLFIRINOX outside major centers is limited; gemcitabine-based regimens remain more accessible but less effective.

• FOLFIRINOX (5-FU, oxaliplatin, irinotecan, leucovorin) — preferred for fit patients
• Gemcitabine monotherapy — for elderly or unfit patients
• Gemcitabine + Capecitabine — alternative to FOLFIRINOX
• Duration: 6 months total perioperative chemotherapy (neoadjuvant + adjuvant combined)

Neoadjuvant Chemotherapy (Pre-Operative)

Neoadjuvant chemotherapy given before surgery is increasingly used for locally advanced resectable and borderline resectable pancreatic cancer to improve outcomes. The rationale includes: downsizing tumors to increase R0 resection rates, treating occult micrometastases early, testing chemoresponsiveness before committing patient to surgery, and allowing time to identify patients with aggressive disease (rapidly progressive on preoperative imaging) who may not benefit from resection.

FOLFIRINOX-based neoadjuvant therapy is now standard for borderline resectable and locally advanced resectable pancreatic cancer. Typical neoadjuvant duration is 2-4 months, followed by restaging imaging. If response is adequate and resectability confirmed, surgery proceeds. If progression or unresectable on restaging, chemotherapy continues and/or radiation therapy considered. Response rates to FOLFIRINOX are 30-40%, with notable downsizing in responders.

Gemcitabine-based neoadjuvant therapy is used when FOLFIRINOX not feasible due to comorbidities or poor functional status. Recent studies suggest combination gemcitabine/nab-paclitaxel may rival FOLFIRINOX efficacy with better tolerability in some patient populations. Neoadjuvant approach has become standard of care for locally advanced resectable tumors in Western centers; adoption in India is slower due to resource constraints and need for experienced multidisciplinary teams.

• FOLFIRINOX (5-FU, oxaliplatin, irinotecan, leucovorin) — standard neoadjuvant
• Gemcitabine + Nab-Paclitaxel — alternative with potentially better tolerability
• Gemcitabine monotherapy — for unfit patients
• Duration: 2-4 months with restaging before surgery

Palliative Chemotherapy for Metastatic Disease

For patients with metastatic (stage IV) pancreatic cancer, systemic chemotherapy is the cornerstone of treatment and improves median survival from 3-4 months (supportive care alone) to 8-12 months. The two primary regimens are FOLFIRINOX and gemcitabine plus nab-paclitaxel (Abraxane), both demonstrating superior efficacy to gemcitabine monotherapy in randomized trials.

FOLFIRINOX (5-FU, oxaliplatin, irinotecan, leucovorin) in the ACCORD11 trial improved median OS from 6.8 to 11.1 months and median PFS from 3.3 to 6.4 months compared to gemcitabine monotherapy. However, FOLFIRINOX is toxic (grade 3-4 neutropenia 45%, febrile neutropenia 5-11%, neuropathy 9%) and reserved for fit patients with ECOG PS 0-1. Dose modifications and supportive care (G-CSF prophylaxis) are routinely employed.

Gemcitabine plus nab-paclitaxel (Abraxane) improved median OS from 6.6 to 8.5 months versus gemcitabine alone and is better tolerated than FOLFIRINOX, with less hematologic toxicity and neuropathy but more neuropathy risk. This regimen is preferred for elderly patients or those with comorbidities precluding FOLFIRINOX. Gemcitabine monotherapy remains acceptable for very elderly (>80) or frail patients with comorbidities, though with inferior outcomes.

Treatment continues until disease progression, unacceptable toxicity, or patient preference for best supportive care. Maintenance therapy continuation (e.g., ongoing gemcitabine after gemcitabine/nab-paclitaxel) may be considered for responding patients, though standard practice varies. In India, FOLFIRINOX costs INR 150,000-200,000 per cycle (4 cycles); gemcitabine/nab-paclitaxel costs INR 80,000-120,000 per cycle, affecting treatment selection significantly.

• FOLFIRINOX (5-FU 400 mg/m² bolus + 2400 mg/m² infusion, oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin) — every 2 weeks
• Gemcitabine 1000 mg/m² + Nab-Paclitaxel 125 mg/m² — weekly x3 of 4
• Gemcitabine 1000 mg/m² monotherapy — weekly
• Continue until progression, toxicity, or patient preference

Targeted Therapies for Specific Molecular Alterations

Recent advances in molecular profiling have identified actionable mutations in pancreatic cancer allowing targeted therapy approaches beyond cytotoxic chemotherapy. BRCA1/BRCA2 mutations, found in 5-10% of pancreatic cancers, confer sensitivity to platinum-based chemotherapy and PARP inhibitors (olaparib). Patients with BRCA-mutant metastatic pancreatic cancer responding to platinum-based chemotherapy benefit from maintenance olaparib therapy, which improves PFS from 3.8 to 7.4 months.

Microsatellite instability (MSI) or mismatch repair deficiency (dMMR), found in 1-3% of pancreatic cancers, predicts immunotherapy responsiveness. Pembrolizumab, a PD-1 inhibitor, has demonstrated durable responses in MSI-H/dMMR pancreatic cancers, with response rates around 30-40%. All pancreatic cancer patients should undergo tumor sequencing (via NGS panel testing) to identify BRCA mutations, MSI status, and other actionable alterations (KRAS, TP53, CDKN2A, SMAD4, BRCA2, PALB2) to guide precision oncology approaches.

KRAS mutations are nearly universal (>90%) in pancreatic cancer but historically not directly targetable. Emerging therapemic agents like sotorasib (KRAS G12C inhibitor) are being studied in KRAS-mutant pancreatic cancer, though G12C mutations are found in <5% of pancreatic cancers. Other emerging targets include SMAD4 loss (potential vulnerability to TGF-beta pathway inhibition), BRCA2/PALB2 mutations (PARP inhibitor sensitivity), and FGFR fusions (FGFR inhibitor sensitivity). Molecular profiling is becoming standard of care to identify treatment opportunities.

• Olaparib (PARP inhibitor) — for BRCA1/BRCA2-mutant metastatic disease, maintenance after platinum chemotherapy
• Pembrolizumab (PD-1 inhibitor) — for MSI-H or dMMR tumors
• Sotorasib (KRAS G12C inhibitor) — for KRAS G12C-mutant tumors (limited prevalence in pancreatic cancer)
• Molecular profiling: NGS panel for BRCA, MSI, KRAS, TP53, CDKN2A, SMAD4, PALB2, FGFR

Radiation Therapy

Radiation therapy (RT) plays an adjunctive role in pancreatic cancer, primarily in locally advanced unresectable disease. Hypofractionated stereotactic body radiation therapy (SBRT) delivers high-dose radiation in few fractions (15-25 Gy in 3-5 fractions) with improved local control and acceptable toxicity compared to conventional external beam radiation therapy (EBRT). SBRT can be considered for locally advanced unresectable pancreatic cancer after chemotherapy plateau or for oligometastatic disease.

Conventional EBRT with concurrent gemcitabine chemotherapy has been used for locally advanced unresectable pancreatic cancer, though routine use in metastatic disease is not recommended due to toxicity and limited survival benefit. Role of RT in resectable disease receiving perioperative chemotherapy is limited; adjuvant RT is considered in marginal margins (R1) or high-risk features. Intraoperative radiation therapy (IORT) is experimental and not standard of care.

RT toxicities include nausea, diarrhea, and late toxicity risk (ulceration, fistula) if high doses delivered near duodenum or stomach. Modern techniques (IMRT, SBRT) reduce normal tissue dose. RT should be delivered by experienced radiation oncologists at tertiary centers with capacity for image-guided radiation therapy (IGRT) to ensure accuracy and minimize toxicity.

• Stereotactic Body Radiation Therapy (SBRT) — 15-25 Gy in 3-5 fractions for locally advanced unresectable
• Conventional External Beam Radiation Therapy (EBRT) — 50-54 Gy in 25-28 fractions (used less commonly now)
• Concurrent chemotherapy: gemcitabine or capecitabine
• Adjuvant RT: for marginal (R1) resection, high-risk features

Supportive Care and Symptom Management

Comprehensive supportive care is essential in pancreatic cancer management given the aggressive nature, high symptom burden, and significant toxicities of treatment. Management of pain is a priority: opioid analgesics are often needed; regional blocks (celiac plexus block) provide superior pain relief and opioid-sparing effect for visceral pain in locally advanced/metastatic disease. Pancreatic enzyme supplementation (pancrelipase) addresses malabsorption and steatorrhea from pancreatic insufficiency, improving nutrition and quality of life.

Biliary and gastric stent placement addresses obstructive jaundice and gastric outlet obstruction respectively, improving quality of life and allowing continued oral intake. Endoscopic biliary stent placement resolves jaundice-related symptoms (itching, dark urine, pale stools) and normalizes bilirubin in majority of patients with unresectable head tumors. Gastric stent or surgical bypass manages gastric outlet obstruction when present.

Nutritional support via dietitian and medical nutritionist addresses cancer cachexia, pancreatic insufficiency-related malabsorption, and treatment-related anorexia. Medium-chain triglyceride supplementation helps with fat malabsorption. Diabetes management becomes complex: insulin requirements often increase with pancreatic insufficiency; oral hypoglycemic agents may be insufficient. Psychosocial support (mental health counseling, support groups) addresses psychological distress and anxiety common in advanced pancreatic cancer. Palliative care involvement early in disease course improves symptom control and quality of life.

• Opioid analgesics (morphine, fentanyl, oxycodone) — for cancer pain
• Celiac plexus block — for visceral pain in locally advanced/metastatic disease
• Pancreatic enzyme replacement (pancrelipase) — for pancreatic insufficiency and malabsorption
• Insulin and oral hypoglycemic agents — for diabetes management
• Proton pump inhibitors — for acid reflux and gastroduodenal protection
• Antiemetics (5-HT3 antagonists, NK1 antagonists, dexamethasone) — for chemotherapy-related nausea
• Loperamide — for diarrhea
• Psychosocial support, palliative care, nutritional counseling

Why Adjuvant Therapy Matters After Surgery

Surgical resection alone is insufficient for pancreatic cancer cure. Even with complete surgical resection (R0 margins), microscopic disease remains in 80-85% of patients, leading to rapid recurrence and death within 1-2 years without systemic therapy. Adjuvant chemotherapy addresses occult micrometastases and improves both disease-free survival and overall survival substantially.

The landmark ESPAC-4 trial (2017) randomized 732 resected pancreatic cancer patients to gemcitabine alone versus gemcitabine plus capecitabine. Adjuvant combined therapy improved median OS from 20.2 to 28.8 months (43% improvement) and median disease-free survival from 7.7 to 13.5 months. More recently, PRODIGE-24 (2021) compared FOLFIRINOX to gemcitabine in adjuvant setting, showing median OS of 54.4 months with FOLFIRINOX versus 35 months with gemcitabine — a remarkable 55% improvement in median survival.

These dramatic survival benefits establish adjuvant chemotherapy as standard of care for all resected pancreatic cancer patients with acceptable performance status. FOLFIRINOX is preferred for fit patients (age <75, ECOG PS 0-1, normal organ function); gemcitabine-based therapy is used for elderly or unfit patients. The cumulative benefit of perioperative chemotherapy (neoadjuvant + adjuvant) is greatest, with some studies showing median OS exceeding 5 years in responding patients — fundamentally changing the prognosis of this once-uniformly fatal disease.

In India, access to adjuvant therapy is suboptimal: many resected patients do not receive any systemic therapy due to cost (INR 150,000+ per cycle), lack of awareness, or physician practice patterns favoring observation. Education of surgical and oncology teams about adjuvant therapy benefits is critical to improve outcomes at the population level.

A Day at HealOnco: Pancreatic Cancer Patient Journey

Treatment Cost Scenarios for Pancreatic Cancer in India

Pancreatic cancer treatment costs in India vary substantially by disease stage, treatment modality selected, and whether care is obtained at government institutions, private centers, or combination thereof. This table reflects approximate INR costs for major treatment scenarios, exclusive of hospitalization and supportive care. Costs are from major metropolitan centers (Delhi, Mumbai, Bangalore); secondary tier cities may have 20-30% lower costs. Insurance coverage varies; many polices exclude pre-existing conditions or cap coverage. Government programs (Ayushman Bharat, state-specific schemes) provide limited coverage for selected treatments.

Cost figures are approximate and reflect major metropolitan center rates (2026). Actual costs vary by hospital, treating physician, drug sourcing, and negotiated rates with insurance companies. Government institution costs are substantially lower but availability of modern chemotherapy regimens (FOLFIRINOX) is limited. Private sector offers advanced therapies and faster access but at 3-5x government costs. Many Indian families face catastrophic health expenditure for pancreatic cancer treatment; financial counseling and assistance programs are essential. Ayushman Bharat and state-specific insurance schemes may cover portions of treatment; patients should verify eligibility upfront. Pancreatic cancer treatment often requires 12-18 months of continuous care; budgeting for cumulative costs is critical.

Our Pancreatic Cancer Specialists

Our Centres

Modern Pancreatic Cancer Care vs. Traditional Approaches

Weighing Treatment Options: Benefits and Drawbacks

Surgical Resection: Offers only true chance for cure with 5-year survival exceeding 20-30% in well-selected early-stage patients at high-volume centers. Drawback: major operation with perioperative morbidity (fistula, infection, bleeding); only 20-25% of patients resectable; requires extended recovery (4-6 weeks). Decision requires careful patient selection and discussion of realistic outcomes.

FOLFIRINOX Chemotherapy: Superior efficacy compared to gemcitabine with significantly improved survival (median OS 54.4 months adjuvant, 11.1 months metastatic). Drawback: higher toxicity profile (grade 3-4 neutropenia 45%, neuropathy 9%, hospitalization risk); requires fit patients with normal organ function and good performance status; not suitable for elderly (>75) or those with comorbidities. Demanding treatment requiring excellent supportive care and patient tolerance.

Gemcitabine/Nab-Paclitaxel: Better-tolerated alternative to FOLFIRINOX with improved survival compared to gemcitabine monotherapy (8.5 months metastatic vs 6.6 months). Drawback: less effective than FOLFIRINOX overall; peripheral neuropathy risk; requires weekly dosing for 3 weeks per month (more frequent hospital visits). Good balance of efficacy and tolerability for elderly or unfit patients.

Neoadjuvant Therapy: Downsizes tumors to increase R0 resection rates; assesses chemoresponsiveness; identifies aggressive disease not worth operating on. Drawback: 2-4 months treatment delay before surgery; some patients progress on therapy precluding resection; requires specialized multidisciplinary expertise unavailable outside tertiary centers. Optimal for borderline resectable and locally advanced resectable disease.

Adjuvant Therapy: Dramatically improves survival (54.4 months with FOLFIRINOX vs 35 months with gemcitabine). Drawback: significant toxicity burden when already recovering from major surgery; 6-month treatment duration with repeated hospitalizations; cost prohibitive for many in India (INR 1,200,000+). Standard of care but access challenging in resource-limited settings.

Targeted Therapy (Olaparib, Pembrolizumab): Precision medicine approach improving outcomes in specific molecular subtypes (BRCA-mutant, MSI-H). Drawback: applicable only to 5-10% of patients with actionable mutations; requires expensive molecular testing (INR 80,000+); olaparib very expensive (INR 300,000+/month); limited insurance coverage in India. Exciting but accessible only to select high-risk populations.

Radiation Therapy (SBRT): Non-invasive option for locally advanced unresectable disease with good local control. Drawback: does not address systemic disease (metastases); toxicity to adjacent organs (duodenum, stomach) if high doses; requires specialized equipment and expertise (IGRT, motion management) available only at major centers. Best used as adjunct to systemic therapy.

Pain Management (Celiac Plexus Block): Superior pain relief for visceral pain with opioid-sparing effect, improving quality of life. Drawback: invasive procedure with rare but serious complications (alcohol toxicity, vascular injury); requires experienced interventional radiologist; temporary effect requiring repeat procedures; not suitable for coagulopathic patients.

Palliative Care Involvement: Early integration improves symptom control, quality of life, and psychological well-being; reduces unnecessary aggressive interventions at end-of-life. Drawback: patients/families may perceive palliative care as “giving up” when actually it augments active treatment; requires specialist availability (limited in secondary tier cities); insurance coverage variable.

Best Supportive Care (No Active Treatment): Avoids chemotherapy toxicity; focused on comfort and quality of life; appropriate for very elderly/frail with ECOG PS >2 or severe comorbidities. Drawback: median survival only 3-4 months; foregoes potential benefit of modern chemotherapy; associated with poor symptom control and caregiver burden. Reserved for carefully selected patients unwilling or unable to tolerate active therapy.

Managing Side Effects of Pancreatic Cancer Treatment

Read the full side effects guide for Pancreatic Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Pancreatic Cancer Treatment in Top Cities

Pancreatic Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):33-60. www.ncbi.nlm.nih.gov
2. Iyer G, Srivastava P, Sharma S, et al. Incidence and epidemiology of pancreatic cancer in India: a review. J Glob Oncol. 2019;5:21-30. www.ncbi.nlm.nih.gov
3. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406. pubmed.ncbi.nlm.nih.gov
4. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703. pubmed.ncbi.nlm.nih.gov
5. Goral V. Pancreatic cancer epidemiology, diagnosis and screening. J Gastrointest Cancer. 2019;50(3):431-436. pubmed.ncbi.nlm.nih.gov
6. American Cancer Society. Pancreatic cancer facts & figures. Accessed April 2026. www.cancer.org
7. National Comprehensive Cancer Network (NCCN). Pancreatic Adenocarcinoma Version 2.2026. NCCN.org www.nccn.org
8. Balakrishnan A, Fonseca FP, Dhamoon AS. Pancreatic Cancer. StatPearls Publishing, 2026. www.ncbi.nlm.nih.gov
9. Gilmore RM, Golan R, Tabassum DP, et al. Pancreatic ductal adenocarcinoma: surgical resection and systemic therapy. CA Cancer J Clin. 2021;71(5):395-420. pubmed.ncbi.nlm.nih.gov
10. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(8):djv128. pubmed.ncbi.nlm.nih.gov
11. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutant metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327. pubmed.ncbi.nlm.nih.gov
12. Indian Council of Medical Research (ICMR) National Cancer Registry Programme. Three Year Report of Existing ICMR Cancer Registries, 2023. icmr.nic.in